Mi Ju Park

Title: Mi Ju Park: Innovator in Dual-Target Antibody Technology

Introduction

Mi Ju Park is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of dual-target antibodies. With a total of 2 patents, his work is paving the way for advancements in pharmaceutical compositions.

Latest Patents

Mi Ju Park's latest patents include a novel form of a dual-target antibody that specifically targets VEGFR-2 and DLL4. This invention encompasses a gene encoding the antibody, a recombinant expression vector that includes the gene, and host cells transformed with this vector. Additionally, the patent details a method for producing the dual-target antibody using these host cells, along with a pharmaceutical composition that comprises the dual-target antibody.

Career Highlights

Mi Ju Park is currently associated with Pharmabcine Inc., where he continues to innovate in the field of antibody technology. His work is crucial in developing therapies that can effectively target specific pathways in diseases, particularly in cancer treatment.

Collaborations

Mi Ju Park collaborates with notable colleagues, including Joong Kyu Kim and Jin San Yoo, who contribute to the research and development efforts at Pharmabcine Inc. Their teamwork enhances the potential for groundbreaking discoveries in the pharmaceutical industry.

Conclusion

Mi Ju Park's contributions to dual-target antibody technology exemplify the innovative spirit of modern biotechnology. His patents and collaborations are set to make a significant impact on the future of medical treatments.